Search results
Showing 91 to 105 of 671 results for diabetes
Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)
Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making
This indicator covers the proportion of children and young people aged 12 to 18 years with type 2 diabetes who received individual care processes in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 1 diabetes who received individual care processes in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged under 18 years with type 2 diabetes who have had their urinary albumin recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 2 diabetes who have had their smoking status recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 1 diabetes who have had their smoking status recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the proportion of children and young people aged 12 to 18 years with type 1 diabetes who have had their urinary albumin recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes (HTG371)
Evidence-based recommendations on implantation of a duodenal-jejunal bypass liner for managing type 2 diabetes. This involves attaching a liner as a barrier between food and the upper part of the bowel, with the aim of lowering blood sugar levels.
Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]
Topic prioritisation
Semaglutide for treating type 2 diabetes in people 10 to 17 years [TSID12249]
Topic prioritisation
Canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) (TA1137)
NICE is unable to make a recommendation on canagliflozin (Invokana) for treating type 2 diabetes in children and young people 10 to 17 years. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1137
Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) (TA1006)
NICE is unable to make a recommendation about the use in the NHS of empagliflozin (Jardiance) for treating type 2 diabetes in people aged 10 to 17 years. This is because Boehringer Ingelheim did not provide an evidence submission.
Show all sections
Sections for TA1006
In development Reference number: GID-TA11644 Expected publication date: 22 October 2026